跳至主導覽
跳至搜尋
跳過主要內容
國立陽明交通大學研發優勢分析平台 首頁
English
中文
在 國立陽明交通大學研發優勢分析平台 搜尋內容
首頁
人員
單位
研究成果
計畫
獎項
活動
貴重儀器
影響
Coagulation abnormalities in sepsis
Cheng Ming Tsao
*
, Shung Tai Ho
, Chin Chen Wu
*
此作品的通信作者
醫學系麻醉學科
研究成果
:
Review article
›
同行評審
32
引文 斯高帕斯（Scopus）
總覽
指紋
指紋
深入研究「Coagulation abnormalities in sepsis」主題。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Keyphrases
Sepsis
100%
Coagulation Abnormalities
100%
Disseminated Intravascular Coagulation
33%
Activated Protein C
33%
Coagulation Activation
33%
Pathophysiology
16%
Randomized Controlled Trial
16%
Clinical Trials
16%
Activation Function
16%
Acetylsalicylic Acid
16%
Clinical Data
16%
Inflammatory Response
16%
Therapeutic Effect
16%
Scoring Algorithm
16%
Blood Coagulation
16%
Improved Outcomes
16%
Antithrombin
16%
Thrombomodulin
16%
Anticoagulants
16%
Validation Trial
16%
Subgroup Analysis
16%
Response to Infection
16%
Response-outcome
16%
Antiplatelet Agents
16%
Bleeding Risk
16%
Vascular Thrombosis
16%
Organ Failure
16%
Thromboelastography
16%
Multiple Organ Dysfunction
16%
Anticoagulant Agents
16%
Bleeding Manifestations
16%
Antiplatelet Drugs
16%
Test Scoring
16%
Sepsis Treatment
16%
Acute Disseminated Intravascular Coagulation
16%
Platelet Factors
16%
Platelet Function
16%
Coagulation Factors
16%
Glycoprotein IIb/IIIa Inhibitors
16%
P2Y12 Inhibitors
16%
Medicine and Dentistry
Sepsis
100%
Disseminated Intravascular Coagulation
42%
Antiplatelet Drug
28%
Pathophysiology
14%
Randomized Controlled Trial
14%
Infection
14%
Clinical Trial
14%
Hemostat
14%
Serositis
14%
Therapy Effect
14%
Laboratory Test
14%
Blood Clotting
14%
Subgroup Analysis
14%
Thrombosis
14%
Antithrombotic
14%
Thrombomodulin
14%
Acetylsalicylic Acid
14%
Anticoagulant
14%
Thromboelastography
14%
Thrombocyte Function
14%
Thrombocyte Factor
14%
Procoagulant
14%
Antithrombin
14%
Fibrinogen Receptor Antagonist
14%
Art Therapy
14%
Blood Clotting Factor
14%
Drotrecogin Alfa
14%
Activated Protein C
14%
Pharmacology, Toxicology and Pharmaceutical Science
Sepsis
100%
Disseminated Intravascular Clotting
42%
Anticoagulant Agent
28%
Antithrombocytic Agent
28%
Inflammation
14%
Infection
14%
Pathophysiology
14%
Clinical Trial
14%
Acetylsalicylic Acid
14%
Randomized Controlled Trial
14%
Therapeutic Effect
14%
Blood Clotting Factor
14%
Antithrombin
14%
Thrombosis
14%
Hemostatic Agent
14%
Thrombomodulin
14%
Fibrinogen Receptor Antagonist
14%
Procoagulant
14%
Activated Protein C
14%
Drotrecogin
14%
Thrombocyte Factor
14%